FI3713572T3 - Takykardian hoito - Google Patents

Takykardian hoito

Info

Publication number
FI3713572T3
FI3713572T3 FIEP18804633.8T FI18804633T FI3713572T3 FI 3713572 T3 FI3713572 T3 FI 3713572T3 FI 18804633 T FI18804633 T FI 18804633T FI 3713572 T3 FI3713572 T3 FI 3713572T3
Authority
FI
Finland
Prior art keywords
yhdiste
joka
methyl
ääää
phenyl
Prior art date
Application number
FIEP18804633.8T
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Inventor
Jan Magnus Aronsen
Jonas Skogestad
Original Assignee
Oslo Univ Hospital Hf
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oslo Univ Hospital Hf filed Critical Oslo Univ Hospital Hf
Application granted granted Critical
Publication of FI3713572T3 publication Critical patent/FI3713572T3/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
FIEP18804633.8T 2017-11-23 2018-11-23 Takykardian hoito FI3713572T3 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17203377 2017-11-23
PCT/EP2018/082450 WO2019101970A1 (en) 2017-11-23 2018-11-23 Treatment of tachycardia

Publications (1)

Publication Number Publication Date
FI3713572T3 true FI3713572T3 (fi) 2025-09-09

Family

ID=60452486

Family Applications (1)

Application Number Title Priority Date Filing Date
FIEP18804633.8T FI3713572T3 (fi) 2017-11-23 2018-11-23 Takykardian hoito

Country Status (12)

Country Link
US (2) US11419874B2 (https=)
EP (1) EP3713572B1 (https=)
JP (2) JP2021504466A (https=)
CN (1) CN111447930A (https=)
AU (1) AU2018371216B2 (https=)
CA (1) CA3083176A1 (https=)
DK (1) DK3713572T3 (https=)
ES (1) ES3039584T3 (https=)
FI (1) FI3713572T3 (https=)
PL (1) PL3713572T3 (https=)
PT (1) PT3713572T (https=)
WO (1) WO2019101970A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11219642B1 (en) * 2020-09-01 2022-01-11 Catherine Lueninghoener Methods and compositions for treating heart conditions
CN113063804B (zh) * 2021-03-16 2022-07-15 太原科技大学 一种基于图像处理的热切机视觉系统自动定位方法
EP4334293A1 (en) * 2021-05-07 2024-03-13 Merck Sharp & Dohme LLC Cycloalkyl 3-oxopiperazine carboxamides and cycloheteroalkyl 3-oxopiperazine carboxamides as nav1.8 inhibitors

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10064105A1 (de) 2000-12-21 2002-06-27 Bayer Ag Neue Substituierte Imidazotriazinone
US20060128695A1 (en) 2002-10-30 2006-06-15 Neuro3D Cyclic nucleotide phosphodiesterase inhibitors, preparation and uses
EP1601675A1 (en) * 2003-03-04 2005-12-07 ALTANA Pharma AG Purin-6-one-derivatives
AU2004268387A1 (en) 2003-08-28 2005-03-10 Nycomed Gmbh Composition comprising a pulmonary surfactant and a PDE2 inhibitor
WO2005035505A2 (en) 2003-09-30 2005-04-21 Artesian Therapeutics, Inc. Compounds with phosphodiesterase inhibiting and calcium channel blocking activities
WO2005041957A1 (en) 2003-10-29 2005-05-12 Pfizer Products Inc. Oxindole derivatives and their use as phosphodiesterase type 2 inhibitors
ATE387446T1 (de) 2003-12-16 2008-03-15 Pfizer Prod Inc Pyrido(2,3-d)pyrimidin-2,4-diamine als pde-2- inhibitoren
EP1548011A1 (en) 2003-12-23 2005-06-29 Neuro3D Benzo[1,4]diazepin-2-one derivatives as phosphodiesterase PDE2 inhibitors, preparation and therapeutic use thereof
AU2005279221C9 (en) 2004-09-02 2012-08-23 Takeda Gmbh Triazolophthalazines
EP1874775B1 (en) 2005-01-05 2012-10-10 Nycomed GmbH Triazolophthalazines as pde2-inhibitors
BRPI0606379A2 (pt) 2005-01-05 2009-06-23 Nycomed Gmbh triazolftalazinas
EP1749824A1 (en) 2005-08-03 2007-02-07 Neuro3D Benzodiazepine derivatives, their preparation and the therapeutic use thereof
DE102006048693A1 (de) 2006-10-14 2008-04-17 Bayer Healthcare Ag Inhibition der PDE2A
EP2279009A4 (en) * 2008-05-05 2011-09-21 Univ Rochester METHOD AND COMPOSITIONS FOR TREATING OR PREVENTING PATHOLOGICAL CARDIAL REMODELING AND HEART FAILURE
US20100120762A1 (en) 2008-11-07 2010-05-13 Wyeth Triazine derivatives as inhibitors of phosphodiesterases
US9540379B2 (en) 2011-01-31 2017-01-10 Boehringer Ingelheim International Gmbh (1,2,4)triazolo[4,3-A]quinoxaline derivatives as inhibitors of phosphodiesterases
KR101548443B1 (ko) 2011-02-23 2015-08-28 화이자 인코포레이티드 신경 장애의 치료를 위한 이미다조[5,1-f][1,2,4]트라이아진
SG195085A1 (en) 2011-06-07 2013-12-30 Pfizer Pyrazolo[3,4-d]pyrimidine compounds and their use as pde2 inhibitors and/or cyp3a4 inhibitors
BR112013033375B1 (pt) 2011-06-27 2022-05-10 Janssen Pharmaceutica N.V Derivados de 1-aril-4-metil-[1,2,4]triazolo[4,3-a]quinoxa-lina, seu uso, composição farmacêutica que os compreende, processo de preparação dos mesmos, solução estéril e composto intermediário
MX361539B (es) 2012-04-25 2018-12-10 Takeda Pharmaceuticals Co Compuesto heterociclico nitrogenado.
EP2873669A4 (en) 2012-07-13 2015-11-25 Takeda Pharmaceutical HETEROCYCLIC CONNECTION
US20140045856A1 (en) 2012-07-31 2014-02-13 Boehringer Ingelheim International Gmbh 4-Methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes
JPWO2015012328A1 (ja) 2013-07-24 2017-03-02 武田薬品工業株式会社 複素環化合物
JP2017114764A (ja) * 2014-04-25 2017-06-29 武田薬品工業株式会社 片頭痛治療剤
US10239882B2 (en) 2014-11-05 2019-03-26 Dart Neuroscience (Cayman) Ltd. Substituted 5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-amine compounds as PDE2 inhibitors

Also Published As

Publication number Publication date
CN111447930A (zh) 2020-07-24
ES3039584T3 (en) 2025-10-22
DK3713572T3 (da) 2025-08-25
US20200345744A1 (en) 2020-11-05
JP2021504466A (ja) 2021-02-15
PT3713572T (pt) 2025-08-28
EP3713572A1 (en) 2020-09-30
JP2024012483A (ja) 2024-01-30
PL3713572T3 (pl) 2025-09-22
US11419874B2 (en) 2022-08-23
AU2018371216A1 (en) 2020-06-04
EP3713572B1 (en) 2025-07-30
WO2019101970A1 (en) 2019-05-31
CA3083176A1 (en) 2019-05-31
US20220362251A1 (en) 2022-11-17
AU2018371216B2 (en) 2024-09-19

Similar Documents

Publication Publication Date Title
FI3713572T3 (fi) Takykardian hoito
BR9713027A (pt) Derivados de pirazol úteis como herbicidas
TW200502230A (en) Dual nk1/nk3 derivatives
IE890026L (en) Substituted pyrrole, pyrazole and triazole angiotensin II antagonists
MX2010009414A (es) Derivados de imidazo-[1,2-b]-piridazina para el tratamiento de enfermedad mediada por cinasa de tirosina c-met.
CA2649775A1 (en) Pyridine[3,4-b]pyrazinones
CA2161857A1 (en) Oxazolidinone derivatives as adhesion receptor antagonists
WO2009156951A3 (en) 5,6,7,8-tetrahydro-imidazo[1,5-a]pyrazine compounds
BRPI0107403B8 (pt) Compostos de n-(5,7-dimetóxi[1,2,4]triazolo[1,5-alfa]pirimidin-2-il) arilsulfonamida e o uso dos mesmos como herbicidas.
SG189499A1 (en) Alpha-7 nicotinic receptor modulators for the treatment of pain, a psychotic disorder, cognitive impairment or alzheimer's disease
PL1756086T3 (pl) Pirydyn-4-ylo-etynylo-imidazole i pirazole jako antagoniści receptora mGlu5
CN102657195A (zh) 一种带消毒功能的洗手液或洗衣液的添加剂及其制备方法
JP7693645B2 (ja) 除草剤としての置換ピリダジノン
MA33385B1 (fr) Acide trans-4-[[(5s)-5-[[[3,5-bis (trifluorométhyl) phényl] méthyl] (2-méthyl-2h-tétrazol-5-yl) amino]-2,3,4,5-tétrahydro-7,9-diméthyl-1h-1-benzazépin-1-yl] méthyl]-cyclohexane carboxylique
EA200201053A1 (ru) Применение брадикардических средств для лечения связанных с гипертрофией заболеваний миокарда и новые комбинированные лекарственные средства
AU2005300691A1 (en) Combinations of nicotinic acetylcholine alpha 7 receptor agonists
NO20070148L (no) Nye oksabispidinforbindelser og deres anvendelse ved behandling av forstyrrelser i hjerterytmen
NZ519126A (en) Novel IL-8 receptor antagonists
WO2002028863A8 (en) New oxabispidine compound useful in the treatment of cardiac arrhythmias
GB0003256D0 (en) Heterocyclic compounds and their therapeutic use
US20210289859A1 (en) Devices, method and kits for reducing transmission of fecal pathogens
US2999047A (en) Bactericidal composition
MXPA04003278A (es) Derivados de 5-metoxi-8-aril-?1,2,4?triazolo?1,5-a?piridina como antagonistas del receptor de adenosina.
JPH01308253A (ja) ２―（３―ピリジル）プロパンニトリル誘導体、その製法及びその用途
HUT70173A (en) 3-benzoyl-3,7-diazabicyclo[3.3.1] nonane compounds and pharmaceutical compositions containing them